Skip to content

Prospective cohort study of pharmacological versus surgical treatment of OMA patients with fertility needs

Prospective cohort study of pharmacological versus surgical treatment of OMA patients with fertility needs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075740
Enrollment
Unknown
Registered
2023-09-14
Start date
2023-06-05
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: (1)Signed informed consent form. (Specific grouping according to patient's wishes) (2) Aged 20-35 years with fertility requirements (3) Meet the clinical diagnostic criteria for endometriosis ( Guidelines for the management of endometriosis (3rd edition)) (4) Typical ultrasonographic (transrectal/transabdominal/transvaginal) presentation of an ovarian endometriosis cyst ( Guidelines for the Management of Endometriosis (3rd edition)) (5) Maximum diameter of single-compartment cysts / total diameter of multi-compartment cysts of 4-6 cm (6) Patients with primary treatment of endometriosis

Exclusion criteria

Exclusion criteria: (1) Patients involved in other interventional research projects. (2) Patients with poor living status, incapacity or unable to follow up for long periods of time. (3) Patients with other co-morbidities that reduce fertility (e.g. genital tract abnormalities, premature ovarian failure, PCOS, etc.) (4) Patients with a history of previous ovarian surgery or other causes of pelvic pain. (5) Excessive rise in CA125 within a short period of time or rapid cyst enlargement of a nature not excluding malignancy. (6) Receiving hormonal preparations containing progestins, oestrogens, gonadotropin-releasing hormone analogues, testosterone derivatives, oestrogen antagonists, aromatase inhibitors and other drugs or their derivatives that are thought to affect sex hormone secretion within 3 months. (7) Pregnant or lactating women. (8) Presence of abnormal vaginal bleeding of undetermined origin. (9) Patients with any disease or condition that may worsen under hormonal therapy. (10) Hypersensitivity to any component of the drug to be administered. (11) Ultrasound or MRI suggestive of combined adenomyosis (12) Other indications for surgical treatment of endometriosis.

Design outcomes

Primary

MeasureTime frame
Ovarian reserve function;

Secondary

MeasureTime frame
Health-related quality of life;The relief of pain associated with endometriosis;Size of endometrioma;The patient's overall impression of the treatment effect;Proportion of patients who require medication after surgery;The direct economic costs of different treatments;

Countries

China

Contacts

Public ContactYi Dai

Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences

jacquedai@vip.sina.com+86 186 1102 7788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026